LunarCrush LLM | creator/twitter::1555606459/posts

[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

[@mtheory11bio](/creator/twitter/mtheory11bio)
"$CRVS now up over XXX% in the last year mostly due to anticipation of their two lowest doses in atopic dermatitis"  
[X Link](https://x.com/mtheory11bio/status/1846623122251808843) [@mtheory11bio](/creator/x/mtheory11bio) 2024-10-16T18:43Z 5249 followers, 15.1K engagements


"$LRMR: our drug was generally well tolerated except when it wasnt"  
[X Link](https://x.com/mtheory11bio/status/1972619203401392373) [@mtheory11bio](/creator/x/mtheory11bio) 2025-09-29T11:07Z 5248 followers, 4892 engagements


"1/ $ALEC reduced the number of patients for INFRONT-3 to 90-100 symptomatic patients vs the previous XXX total patients based on a blinded SSRE. They stated that the SSRE demonstrated the variability of disease progression is considerably less than their initial estimates"  
[X Link](https://x.com/mtheory11bio/status/1975602784876830875) [@mtheory11bio](/creator/x/mtheory11bio) 2025-10-07T16:43Z 5248 followers, 2567 engagements


"Like the setup for $TECX as expectations are low heading into the HFrEF + $AZN Re-PHIRE readouts. The primary endpoint for Re-PHIRE is change in PVR vs pbo but w/ the inclusion of ipcPH patients (which have normal PVR) secondary endpoints and subgroups should be more important"  
[X Link](https://x.com/mtheory11bio/status/1978474430461366607) [@mtheory11bio](/creator/x/mtheory11bio) 2025-10-15T14:53Z 5250 followers, 3035 engagements


"$BHVN is interesting because would the FDA say haha j/k in a CRL if troriluzole hit X pre-specified primary and secondary endpoints in the RWE study that the FDA helped design"  
[X Link](https://x.com/mtheory11bio/status/1973743867393699948) [@mtheory11bio](/creator/x/mtheory11bio) 2025-10-02T13:36Z 5250 followers, 17.8K engagements


"@biofeed This shows why technical analysis isnt a great strategy in biotech"  
[X Link](https://x.com/mtheory11bio/status/1980428897893380239) [@mtheory11bio](/creator/x/mtheory11bio) 2025-10-21T00:20Z 5250 followers, 1162 engagements

[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

@mtheory11bio "$CRVS now up over XXX% in the last year mostly due to anticipation of their two lowest doses in atopic dermatitis"
X Link @mtheory11bio 2024-10-16T18:43Z 5249 followers, 15.1K engagements

"$LRMR: our drug was generally well tolerated except when it wasnt"
X Link @mtheory11bio 2025-09-29T11:07Z 5248 followers, 4892 engagements

"1/ $ALEC reduced the number of patients for INFRONT-3 to 90-100 symptomatic patients vs the previous XXX total patients based on a blinded SSRE. They stated that the SSRE demonstrated the variability of disease progression is considerably less than their initial estimates"
X Link @mtheory11bio 2025-10-07T16:43Z 5248 followers, 2567 engagements

"Like the setup for $TECX as expectations are low heading into the HFrEF + $AZN Re-PHIRE readouts. The primary endpoint for Re-PHIRE is change in PVR vs pbo but w/ the inclusion of ipcPH patients (which have normal PVR) secondary endpoints and subgroups should be more important"
X Link @mtheory11bio 2025-10-15T14:53Z 5250 followers, 3035 engagements

"$BHVN is interesting because would the FDA say haha j/k in a CRL if troriluzole hit X pre-specified primary and secondary endpoints in the RWE study that the FDA helped design"
X Link @mtheory11bio 2025-10-02T13:36Z 5250 followers, 17.8K engagements

"@biofeed This shows why technical analysis isnt a great strategy in biotech"
X Link @mtheory11bio 2025-10-21T00:20Z 5250 followers, 1162 engagements